Romanita Nica, MD
Nephrology · Prescott, AZNPI 1366486144
Payments from drug & device makers
Across 347 payments — averaging $913.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$166K
- GSK$136K
- Gilead$8K
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$613
- Amgen$557
- plus $4K from 26 others
What the payments were for
- Food & beverage$6,04296%
- Education$2794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 78 | $166,288 |
| GSK | 26 | $136,380 |
| Gilead | 2 | $8,133 |
| AstraZeneca(2 entities) | 39 | $1,489 |
| Otsuka America Pharmaceutical, Inc. | 48 | $613 |
| Amgen(2 entities) | 26 | $557 |
| OPKO Pharmaceuticals, LLC | 17 | $544 |
| Calliditas Therapeutics US Inc. | 21 | $415 |
| Mallinckrodt Hospital Products Inc. | 10 | $315 |
| Aurinia Pharma U.S., Inc. | 5 | $295 |
| Nxstage Medical, Inc. | 4 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $242 |
| Akebia Therapeutics Inc | 17 | $221 |
| Novo Nordisk | 4 | $179 |
| Travere Therapeutics, Inc. | 11 | $162 |
| Cormedix Inc. | 2 | $135 |
| Veloxis Pharmaceuticals, Inc. | 6 | $133 |
| Novartis | 6 | $132 |
| Outset Medical Inc | 2 | $129 |
| Vifor Pharma, Inc. | 4 | $104 |
| Novo Nordisk Health Care AG | 1 | $45 |
| Boehringer Ingelheim | 2 | $41 |
| Boston Scientific | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$240
- LUPKYNIS$233
- ACTHAR$130
- NXSTAGE SYSTEM ONE$125
- TARPEYO$125
- LIVTENCITY$122
- KRYSTEXXA$121
- LOKELMA$118
- DefenCath$110
How this compares
$316,998 in reported general payments places this provider in the 95th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 37 | $90,989 |
| FarxigaDapagliflozin Propanediol | 84 | $75,349 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $39,214 |
| Sevelamer Carbonate | 80 | $32,650 |
| AuryxiaFerric Citrate | 13 | $29,439 |
| JardianceEmpagliflozin | 32 | $26,126 |
| KerendiaFinerenone | 23 | $23,661 |
| Lanthanum Carbonate | 26 | $19,416 |
| Fluconazole | 253 | $15,385 |
| MyrbetriqMirabegron | 17 | $10,297 |
| Tacrolimus | 67 | $5,613 |
| Calcitriol | 247 | $4,284 |
| Calcium Acetate | 30 | $3,751 |
| Valganciclovir Hcl | 17 | $3,660 |
| Mycophenolate Mofetil | 40 | $3,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,489 | $114,562119 claims |
| Akebia Therapeutics IncAuryxia | $221 | $29,43913 claims |
| Boehringer IngelheimJardiance | $41 | $26,12632 claims |
| BayerKerendia | $166,288 | $23,66123 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $22 | $1,83561 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 nephrology providers in Arizona.
Other nephrology in Prescott
- Andrew SacksPrescott$6K
- Victoria VoPrescott$6K
- Peter SantosGlendale$3.6M
- Minesh RajpalPeoria$3.6M
- Leslie ThomasPhoenix$3.1M
- Kenneth BorenMesa$1.6M
- Hasan KhamashPhoenix$1.3M
- Roxana NeyraPhoenix$1M
- Mandeep SahaniMesa$945K
- Randy CooperPeoria$837K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.